Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 16  |  Issue : 5  |  Page : 1093-1099

Magnetic resonance-guided ablation of liver tumors: A systematic review and pooled analysis


1 Department of Interventional MRI, Shandong Medical Imaging Research Institute Affiliated to Shandong University, Jinan, Shandong; Department of Intervention, Shanghai Fengxian District Central Hospital, Shanghai, China
2 Department of Interventional MRI, Shandong Key Laboratory of Advanced Medical Imaging Technologies and Applications, Shandong Medical Imaging Research Institute Affiliated to Shandong University, Jinan, Shandong, China
3 Department of Nuclear Medicine, Tai'an Central Hospital, Tai'an, Shandong, China
4 Department of Interventional Therapy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
5 The Southwestern Finland Imaging Centre, Turku University Hospital, Turku, Finland

Correspondence Address:
Chengli Li
Department of Interventional MRI, Shandong Key Laboratory of Advanced Medical Imaging Technologies and Applications, Shandong Medical Imaging Research Institute Affiliated with Shandong University, Jinan, Shandong
China
Roberto Blanco
The Southwestern Finland Imaging Centre, Turku University Hospital, Turku
Finland
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jcrt.JCRT_1115_19

Rights and Permissions

Purpose: The purpose of this study is to study the clinical outcomes of different types of magnetic resonance (MR)-guided ablation for the treatment of liver tumors by performing a systematic review and pooled analysis. Materials and Methods: A comprehensive literature search was performed for clinical trials published from January 1997 to October 2019 in PubMed, the Web of Science, Embase, and the Cochrane Library. Pooled analyses were performed to obtain the complete ablation (CA), complication, progression-free survival (PFS), and overall survival (OS) rates. Results: Thirty studies were eligible, including four studies on MR-guided microwave ablation (MWA); 14 studies on MR-guided radiofrequency ablation (RFA); one study on both MR-guided MWA and RFA; eight studies on MR-guided, laser-induced thermotherapy (LITT); two studies on MR-guided percutaneous cryoablation (PC); and one study on MR-guided percutaneous ethanol injection (PEI). The CA rates in patients who underwent RFA, MWA, LITT, PC, and PEI were 95.60%, 98.86%, 77.78%, 47.92%, and 85.71%, respectively. The most frequent complications were pain (27.66%, 13/47) and postablation syndrome (27.66%, 13/47) in the PC group; pleural effusion (8.11%, 119/1,468) and subcapsular hematoma (2.25%, 33/1,468) in the LITT group; pleural effusion (2.67%, 2/75) in the MWA group; and subcapsular hematoma (4.18%, 20/478) and post-ablation syndrome (2.93%, 14/478) in the RFA group. There were few studies reporting PFS and OS. Conclusions: MR-guided ablation is a practicable alternative treatment for liver tumors, especially MR-guided RFA and MWA, which have high rates of CA and low occurrences of complications.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed221    
    Printed0    
    Emailed0    
    PDF Downloaded2    
    Comments [Add]    

Recommend this journal